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Abstract
Background: Airway epithelial cells are critical in host defense against bacteria including Mycoplasma pneumoniae 
(Mp) in chronic obstructive pulmonary disease (COPD) and asthma. β2-agonists are mainstay of COPD and asthma 
therapy, but whether β2-agonists directly affect airway epithelial host defense functions is unclear.
Methods: Epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and COPD (n = 8) subjects were 
grown in air-liquid interface cultures, and treated with cigarette smoke extract (CSE) and/or Th2 cytokine IL-13, 
followed by Mp infection and treatment with β2-agonists albuterol and formoterol for up to seven days. Mp and host 
defense proteins short palate, lung, and nasal epithelial clone 1 (SPLUNC1) and β-defensin-2 were quantified. 
Expression of β2-adrenergic receptors was also measured by real-time quantitative RT-PCR.
Results: (R)- or racemic albuterol and (R,R)- or racemic formoterol significantly decreased Mp levels in normal and 
asthma epithelial cells. Normal cells treated with Mp and (R)- or racemic albuterol showed an increase in SPLUNC1, but 
not in β-defensin-2. COPD cells did not respond to drug treatment with a significant decrease in Mp or an increase in 
SPLUNC1. IL-13 attenuated drug effects on Mp, and markedly decreased SPLUNC1 and β2-adrenergic receptors.
Conclusions: These results for the first time show that β2-agonists enhance host defense functions of primary 
bronchial epithelial cells from normal and asthma subjects, which is attenuated by IL-13.
Background
Bacterial infections are common in the airways of
patients with chronic lung diseases [1-3]. As many as 40%
of stable asthmatics test positive for atypical bacteria in
airway samples[4]. Higher levels of pathogens such as
Mycoplasma pneumoniae (Mp) and Chlamydia pneumo-
niae are associated with more severe asthma symptoms
and increased COPD exacerbations[5,6]. Treatment with
antibiotics such as clarithromycin can improve lung func-
tion in asthma patients with Mp[7]. However , bacterial
infections remain prevalent in patients with chronic lung
diseases, suggesting impaired lung host defense functions
in these patients.
Innate immune response in airway epithelial cells pro-
vides a vital source of host defense molecules to protect
against respiratory infection. For example, large airway
epithelial cells constitutively produce short palate, lung,
and nasal epithelium clone 1 (SPLUNC1), a member of
the PLUNC protein family, which is proposed to exhibit
host defense properties[8]. SPLUNC1 has been shown to
possess antimicrobial and anti-inflammatory func-
tions[9,10]. Bacterial infection increases SPLUNC1 lev-
els. However, in an allergic setting including the Th2
cytokine IL-13, SPLUNC1 levels and Mp clearance are
decreased[10]. Human β-defensins (hβDs) are another
class of antimicrobial proteins produced by epithelial
cells of airways and skin, and are able to kill a broad spec-
trum of bacteria including Mp[11]. hβD-3, closely related
to hβD-2, is shown to be down-regulated by IL-13[12].
β2-agonists are the mainstay of therapy to induce bron-
chodilation in patients suffering from COPD and asthma.
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The drugs work through β2-adrenergic receptors to exert
their functions including relaxation in smooth muscle
cells[13]. The receptors are expressed in various types of
cells in the lung including airway epithelial cells[14]. In
addition to their bronchodilatory effect, β2-agonists have
been shown to reduce the production of inflammatory
cytokines and thereby airway inflammation[15]. More-
over, β2-agonist salmeterol was shown to protect airway
epithelial integrity that was otherwise impaired by
Pseudomonas aeruginosa exoproducts[16]. Interestingly,
activation of β2-adrenergic receptors on human periph-
eral blood T cells could modulate production of Th2
cytokines (e.g., IL-13)[17]. In our previous studies, IL-13
was able to increase bacterial (e.g., mycoplasma) load in
airway epithelial cells[10]. These publications suggest
that β2-agonists may modulate airway epithelial cell host
defense functions. However, there is a lack of direct evi-
dence demonstrating host defense functions of β2-ago-
nists in primary human airway epithelial cells.
Extended use of exogenous antibiotics may cause drug
resistance, thereby becoming less effective at eliminating
chronic infections that are prevalent in COPD and
asthma patients. Therefore, it is beneficial to enhance air-
way production of endogenous antimicrobial substances
to promote the clearance of invading bacteria. In this
study, we seek to identify a novel function of the short-
and long-acting β2-agonists albuterol and formoterol, in
(R)-, (R,R)-, racemic, (S)-, or (S,S)-isomeric forms, which
have different efficacies in bronchodilation [18-20]. Spe-
cifically, we hypothesize that β2-agonists possess an anti-
microbial function by decreasing bacterial levels in
primary human bronchial epithelial cells from normal
subjects, asthmatics, and COPD patients. We predict that
they do so in part through the induction of host defense
molecules SPLUNC1 and hβD-2.
Methods
Study participants, bronchoscopy, and bronchial epithelial 
cell processing
Bronchoscopy with endobronchial epithelial brushings
was performed on 24 human subjects (normal = 8,
asthma = 8, COPD = 8). The clinical characteristics for all
subjects are shown in Table 1. Four of the normal subjects
were non-smokers and four were healthy smokers. Asth-
matics met the American Thoracic Society (ATS) criteria
for mild to moderate asthma. COPD patients had Global
Initiative for COPD (GOLD) stages between II and IV.
Bronchial brushings were performed as previously
described[21] with a single-sheathed cytology brush
(#CF-001, Medical Engineering Laboratory, Durham,
NC). Up to six brushings were obtained per subject. Our
research protocols were approved by the institutional
review board at National Jewish Health, and all subjects
provided written informed consent.
Primary bronchial epithelial cell air-liquid interface cultures
Brushed bronchial epithelial cells were seeded onto 60
mm collagen-coated tissue culture dishes, and incubated
at 37°C with 5% CO2 (Figure 1). At 80% confluence, they
were transferred onto collagen-coated transwell inserts (4
× 104 cells/insert) in 12-well plates[21]. After reaching
confluence under the submerged condition, they were
shifted to air-liquid interface (ALI), and treated with or
without IL-13 (10 ng/ml) and/or 20% cigarette smoke
extract (CSE) to mimic the airways of asthmatics and
smokers with or without COPD. IL-13 concentration was
chosen based on previous publications in human airway
epithelial cell cultures[10,21-23], and measurement of IL-
13 protein in bronchoalveolar lavage fluid of asthmatics
with a segmental allergen challenge[24]. Medium, IL-13,
and/or CSE were replenished every 48 hours for 10 days
to allow cell mucociliary differentiation. Cells were then
infected with Mp and treated with (R)-, racemic, or (S)-
albuterol (10 μM), or (R,R)-, racemic, or (S,S)-formoterol
(10 nM) as shown in Table 2. β2-agonists were provided
by the Sepracor, Inc (Marlborough, MA). The concentra-
tion of albuterol or formoterol was chosen based on pre-
vious publications in human airway epithelial cell
cultures, and was consistent with the dose of effective
therapy in humans [25-30]. On days 1, 3, and 7 post-Mp
infection, an aliquot of apical supernatant was plated
onto PPLO agar plates for Mp quantification. The
remainder was stored at -80°C for quantification of
SPLUNC1 and hβD-2 by ELISA. Seven days post-infec-
tion, cells were harvested into TRIzol (Invitrogen) for
total RNA extraction.
Cigarette smoke extract (CSE) preparation
CSE was prepared daily as previously described with
slight modifications[31]. Mainstream cigarette smoke
w a s  b u b b l e d  i n t o  1 2 . 5  m l  o f  s e r u m - f r e e  c e l l  c u l t u r e
medium. The medium was filter-sterilized, diluted in cell
culture medium to 20%, and applied to the apical side of
the transwells within 30 minutes of preparation.
Mp preparation and culture
Mp was prepared for cell culture as previously
described[10]. To quantify Mp, PPLO agar plates with
epithelial apical supernatant were incubated at 37°C with
5% CO2 for seven days for colony forming unit (CFU)
counting.
Direct effects of β2-agonists on bacterial load in an 
epithelial cell-free environment
To determine if β2-agonists can directly affect bacterial
growth, (R)-, racemic, (S)-albuterol (10 μM) or (R,R)-,
racemic and (S,S)-formoterol (10 nM) or PBS (control)
was incubated in quadruplicate with Mp (4 × 104 CFU per
well, the same number of bacteria as plated on airwayGross et al. BMC Pulmonary Medicine 2010, 10:30
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epithelial cells) in a cell-free 96-well plate. After 2 hours
(a typical time for bactericidal assay), the supernatants
were plated on PPLO agar plates to quantify the bacterial
level.
SPLUNC1 and hβD-2 ELISAs
Our previously developed direct SPLUNC1 ELISA was
performed on the epithelial apical supernatants to quan-
tify SPLUNC1[10].
hβD-2 levels in the apical supernatants were deter-
mined with an ELISA kit (PeproTech, Rocky Hill, NJ).
The plate was coated with a capture antibody (Ab),
blocked with BSA, and then incubated with apical super-
natant, detection Ab and avidin-HRP. The plate was
developed with 2,2'-Azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid).
Real-time quantitative PCR
Reverse transcription and real-time PCR were used to
determine the effect of IL-13 on mRNA expression of the
β2-adrenergic receptor (ADRB2). 1 μg of total RNA was
reverse transcribed with Oligo DT in a 50 μl reaction. A
Taqman Gene Expression Assay (Applied Biosystems,
Foster City, CA) was used to measure ADBR2 mRNA rel-
ative levels using the comparative threshold cycle (CT)
method by normalizing to the housekeeping gene
GAPDH (Applied Biosystems)[21].
Statistical analysis
One-way analysis of variance (ANOVA) was used for
multiple comparisons, and a Tukey's post hoc test was
applied where appropriate. Student's t test was used when
only two groups were compared. A p value ≤ 0.05 was
considered significant.
Results
Impact of β2-agonists on airway epithelial bacterial load 
and SPLUNC1 levels in the absence of IL-13
All data presented is the average of the same conditions at
days 1, 3, and 7 because the trends were consistent across
all three-time points. We analyzed the data in smokers
and non-smokers in each subject group, and did not
observe any significant differences of Mp levels. There-
fore, we combined the data from smokers and non-smok-
ers for further analysis.
To evaluate the overall cell responses to β2-agonists, we
performed an initial data analysis in all 24 subjects from
the three subject groups. (R)-albuterol, racemic albuterol,
(R,R)-formoterol, and racemic formoterol significantly
reduced Mp levels in the apical supernatants from cells
Table 1: Characteristics of human study subjects
Age Sex
(M/F)
Smoking
(pack-years)
FEV1, %
predicted
FVC, %
predicted
FEV1/FVC%
Normal
(n = 8)
52.3 ± 4.3 4/4 4 - 0
4 - 37.0 ± 4.1
97.5 ± 6.8 92.0 ± 6.9 82.8 ± 1.3
COPD
(n = 8)
66.8 ± 1.8 3/5 8 - 67.8 ± 10.8 38.5 ± 7.7 61.4 ± 7.9 46.6 ± 6.7
Asthma
(n = 8)
48.8 ± 7.5 4/4 5 - 0
3 - 17.7 ± 6.7
82.1 ± 9.3 91.5 ± 8.0 69.5 ± 4.5
FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity.
Table 2: Air-liquid interface culture conditions (n = 56) of human primary brushed bronchial epithelial cells from normal 
subjects and patients with asthma and COPD
Drug Medium CSE CSE +
Mp
IL-13 IL-13 +
CSE
IL-13 + CSE
+ Mp
IL-13 +
Mp
Mp
N o  d r u g x x xxxxxx
(R)-albuterol x x x x x x x x
Racemic albuterol x x x x x x x x
(S)-albuterol x x x x x x x x
( R , R ) - f o r m o t e r o l x x xxxxxx
Racemic 
formoterol
x x xxxxxx
( S , S ) - f o r m o t e r o l x x xxxxxx
CSE, cigarette smoke extract; Mp, Mycoplasma pneumoniae.Gross et al. BMC Pulmonary Medicine 2010, 10:30
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treated with Mp (Figure 2A) or Mp + CSE (Figure 2B) as
compared to cells not treated with any drug. (S)-albuterol
and (S,S)-formoterol did not significantly alter Mp load
(data not shown).
Differences in the drug effect on Mp load existed
between subject groups. Among cells treated with Mp or
Mp+CSE, normal subjects showed the strongest drug
effect of decreased Mp burden, including significant (p <
0.05) reduction of Mp levels in four conditions ((R)-
albuterol+Mp, (S)-albuterol+Mp, (R,R)-formot-
erol+Mp+CSE, and (S,S)-formoterol+Mp), as compared
to non-drug-treated cells. Asthmatics showed a moderate
trend, also with some significant (p < 0.05) decreases of
Mp levels in three conditions ((R)-albuterol+Mp, (R,R)-
formoterol+Mp, and Rac-formoterol+Mp). Cells from
COPD patients exhibited the weakest trend for drug
effect in decreasing Mp levels without statistical signifi-
cance (Table 3).
In all subjects combined, SPLUNC1 levels were not sig-
nificantly different with the addition of any of the drugs.
H o w e v e r ,  c e l l s  f r o m  n o r m a l  s u b j e c t s  t r e a t e d  w i t h  M p
plus either (R)- or racemic albuterol significantly
increased SPLUNC1 levels in the apical supernatant (Fig-
ure 3). (R,R)- and racemic formoterol marginally
increased SPLUNC1 (p = 0.1 and p = 0.07, respectively).
In addition, in Mp-infected normal subject cells, (S)-
albuterol trended (p = 0.062) to increase SPLUNC1 pro-
tein levels. Cells from COPD and asthma patients did not
show significantly increased SPLUNC1 following any
drug treatment.
Impact of β2-agonists on airway epithelial bacterial load 
and SPLUNC1 levels in the presence of IL-13
In sharp contrast to cells without IL-13 treatment, cells
treated with IL-13 did not respond to any of the drugs
with lower Mp levels. No clear trend of increase or
decrease of Mp levels was present in the IL-13-treated
cells with the addition of drug. Furthermore, overall Mp
levels in IL-13 treated cells were significantly higher in all
subjects combined (Figure 4A) or in any individual sub-
ject group (data not shown) compared to cells without IL-
13. Accordingly, IL-13 treated cells had significantly
lower SPLUNC1 levels than those without IL-13 (Figure
4B).
Direct effects of β2-agonists on bacterial load in an 
epithelial cell-free environment
Albuterol or formoterol of any isomers, as compared to
PBS (negative control), did not (p = 0.78) affect Mp levels
in an epithelial cell-free environment (Figure 5). These
data suggest that β2-agonists did not have a direct anti-
bacterial (e.g., bactericidal) effect, and may exert their
host defense activity through modulating airway epithe-
lial cell functions.
Impact of IL-13 on β2-adrenergic receptor (ADRB2) mRNA 
Levels
Since cells treated with IL-13 failed to respond to β2-ago-
nists, we determined if IL-13 reduced ADRB2 expression,
rendering drug resistance. mRNA levels of ADRB2 were
quantified in epithelial cells with or without IL-13 treat-
ment. At baseline (no IL-13 treatment), bronchial epithe-
Figure 1 Timeline of primary human bronchial epithelial cell air-liquid interface (ALI) cultures. Cells were seeded in transwells in immersed 
culture for 7 days to allow cell proliferation, and then were shifted to ALI for 10 days to induce mucociliary differentiation. Cigarette smoke extract 
(CSE) and/or IL-13 treatment began with the ALI condition. At day 10, cells were treated with drug and infected with Mycoplasma pneumoniae (Mp). 
Apical supernatants were harvested at days 1, 3, and 7 post-infection, and cells were harvested at day 7 for mRNA analysis of gene of interest using 
real-time RT-PCR. SPLUNC1 = short palate, lung, and nasal epithelial clone 1; and hBD2 = human β-defensin-2.
 Day -17     -10                   0              1          3            6                  7 
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Cigarette smoke, IL-13 or media (control) Gross et al. BMC Pulmonary Medicine 2010, 10:30
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lial cell ADRB2 mRNA levels were not (p = 0.15)
significantly different among normal subjects (ADRB2
mRNA relative level: 15.0 ± 2.5), asthmatics (8.6 ± 2.3)
and COPD patients (13.8 ± 2.3). Compared with the con-
trol (no IL-13), IL-13 treatment significantly decreased
ADRB2 mRNA expression in bronchial epithelial cells
from asthma (Figure 6A) and COPD patients (Figure 6B).
However, IL-13 did not significantly (p = 0.12) reduce
ADRB2 mRNA levels in normal cells.
Impact of β2-agonists on hβD-2 levels
hβD-2 was measured to explain reduced Mp levels fol-
lowing β2-agonist treatment in epithelial cells. However,
unlike the Mp or SPLUNC1 data, no significant differ-
ences were found in hβD-2 levels among any drug treat-
ments, including samples with or without IL-13.
Discussion
In the current study, we demonstrated a novel host
defense function for the short- and long-acting β2-ago-
nists albuterol and formoterol in primary brushed human
bronchial epithelial cells. We found that the drugs were
capable of lowering the Mp burden (up to 40% reduction)
of epithelial cells, and that they appeared to do so in part
through the induction of SPLUNC1, especially in normal
subjects. However, in the COPD cells and in all the cells
treated with IL-13, this drug effect was abolished, possi-
bly through the reduction of SPLUNC1 and β2-adrener-
gic receptor (ADRB2).
Figure 2 Quantification of Mycoplasma pneumoniae (Mp) in the apical supernatants of cultured bronchial epithelial cells. Cells from all three 
subject groups (n = 24) were treated with various isomers of albuterol and formoterol in the presence of Mp only (1 CFU/cell) (A), or Mp (1 CFU/cell) 
+ CSE (20%) (B). Mp levels significantly decreased with by (R)-albuterol [(R)-alb], racemic albuterol [Rac-alb], (R,R)-formoterol [(R,R)-form], and racemic 
formoterol [Rac-form]. The red horizontal bars represent means of data under each cell culture condition. The open white circles indicate normal sub-
jects; the closed purple circles indicate COPD patients; and the green triangles represent asthmatics.
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Table 3: Effects of β2-agonist isomers on Mycoplasma pneumoniae (Mp) load in cultured human airway epithelial cells*
Normal subjects Asthma COPD
Mp Mp + CSE† Mp Mp + CSE Mp Mp + CSE
(R)-albuterol 0.03 0.16 0.03 0.24 0.43 0.14
R a c e m i c  a l b u t e r o l 0 . 1 40 . 0 90 . 0 80 . 1 00 . 0 80 . 1 6
(S)-albuterol 0.01 0.48 0.15 0.21 0.44 0.20
(R,R)-formoterol 0.17 0.03 0.04 0.10 0.07 0.15
Racemic formoterol 0.48 0.10 0.01 0.37 0.13 0.08
(S,S)-formoterol 0.01 0.25 0.77 0.55 0.64 0.24
*, Data are presented as p values. A p value ≤ 0.05 is considered statistically significant. The p values were obtained by comparing β2-agonists 
with no drug treatments. †, CSE = cigarette smoke extract.Gross et al. BMC Pulmonary Medicine 2010, 10:30
http://www.biomedcentral.com/1471-2466/10/30
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Host defense function of β2-agonists in the absence of IL-
13
A certain population of asthmatics has no or very low
Th2 cytokine background[32,33]. Therefore, testing the
effects of β2-agonists without IL-13 is relevant for this
subset of patients. (R)- and racemic albuterol and (R,R)-
and racemic formoterol were found to reduce Mp levels
in human bronchial epithelial cells mainly from normal
subjects and/or asthmatics without IL-13 treatment. Our
results suggest that β2-agonists enhance host defense
functions in the airway mucosa. This decrease was signif-
icant with all 24 subjects combined in both Mp-only and
Mp+CSE conditions. When data were analyzed in indi-
vidual groups of subjects, the cells from the three subject
groups responded differently to drug treatment following
Mp infection. A previous study shows that mucin
MUC5AC mRNA and protein levels can be differentially
regulated in normal versus asthmatic brushed bronchial
epithelial cells ex vivo[34]. The current study finds COPD
cells responded less effectively to β2-agonists compared
with normal and asthmatic cells. In response to β2-ago-
nists, the normal cells had the lowest bacterial load; asth-
matic cells also had significantly lower Mp burden.
However, the COPD cells showed only a slight trend of
decrease in Mp levels. Overall, the COPD cells carried a
Figure 3 SPLUNC1 protein levels in the apical supernatants of 
cultured bronchial epithelial cells. Cells from normal subjects (n = 8) 
were treated with Mycoplasma pneumoniae (Mp, 1 CFU/cell). Both (R)-
albuterol [(R)-alb] and racemic albuterol [Rac-alb] significantly in-
creased SPLUNC1 levels. (R,R)-formoterol [(R,R)-form] and racemic for-
moterol [Rac-form] marginally increased SPLUNC1. The red horizontal 
bars represent means of data under each cell culture condition.
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Figure 4 Quantification of Mycoplasma pneumoniae (Mp) and SPLUNC1 protein levels in the apical supernatants of bronchial epithelial 
cells. Cells from all three subject groups (n = 24) were treated with Mp in the presence or absence of IL-13 (10 ng/ml). IL-13 treatment significantly 
increased Mp levels (A), but dramatically decreased SPLUNC1 levels (B). The red horizontal bars represent means of data under each cell culture con-
dition.
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Figure 5 Mycoplasma pneumoniae (Mp) levels in the superna-
tants of a cell-free 96-well plate. Various isomers of albuterol (10 μM) 
and formoterol (10 nM) or PBS (control, (-)) were incubated in quadru-
plicate with Mp (4 × 104 CFU per well) for 2 hours. Mp levels did not (p 
= 0.78) significantly change following treatments with (R)-albuterol 
[(R)-alb], racemic albuterol [Rac-alb], (S)-albuterol [(S)-alb], (R,R)-formot-
erol [(R,R)-form], racemic formoterol [Rac-form] or (S,S)-formoterol 
[(S,S)-form].
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higher Mp burden than normals or asthmatics, suggest-
ing that the COPD cells had inherently suppressed host
defense against Mp as compared to the other groups. For
example, in the current study, we found that baseline
SPLUNC1 levels in apical supernatants of airway epithe-
lial cells from COPD patients (18073 ± 2577 ng/ml)
trended to be lower than those from normal subjects
(24631 ± 2676 ng/ml, p = 0.14) and asthmatics (25020 ±
4480 ng/ml, p = 0.22).
While the racemic isomers of β2-agonists are used clin-
ically, the (R)- and (R,R)- isomers are known to be the
drugs' active forms. Application of (S)-albuterol and
(S,S)-formoterol resulted in reduced Mp load only in nor-
mal cells, but not cells from asthmatics and COPD
patients. (S)-albuterol has traditionally been thought to
be inert, but studies have shown that the (S)-isomer may
actually increase inflammation and negate the anti-
inflammatory effects of (R)-albuterol[18,19]. It is there-
fore not surprising to observe differing antimicrobial
effects of (S)- and (S,S)-isomers in cells from various
study groups (e.g., normal subjects versus asthma and
COPD patients). The mechanisms by which (S)- or (S,S)-
isomers differ from (R)- or (R,R)-isomers in reducing
bacterial levels remain unclear, and will be addressed in
our future studies. For example, a β2-receptor antagonist
can be used to test whether different isomers act similarly
through β2-receptors.
How β2-agonists increase airway epithelial host
defense functions remains unclear. Our data demonstrate
that albuterol resulted in an increase in secreted
SPLUNC1 levels in normal cells treated with Mp alone.
This corresponded to the decrease in Mp burden seen in
these cells. However, no significant increase of SPLUNC1
existed in the cells treated with both Mp and CSE. Fur-
ther, there was only a slight induction of SPLUNC1 fol-
lowing drug treatment in the asthma cells and none in the
COPD cells. These data indicate that the heightened host
defense can be explained in part, but not entirely, through
increased SPLUNC1 levels, particularly in normal cells.
Conversely, no significant differences were detected in
hβD-2 levels in any of the conditions, suggesting that
hβD-2 may not contribute to increased host defense
through β2-agonists. Other mechanisms may also con-
tribute to the beneficial effects of β2-agonists on airway
epithelial defense against bacterial infection. For example,
Hasani and colleagues demonstrated that albuterol treat-
ment in COPD patients enhanced lung mucociliary clear-
ance[35], but whether this is linked to less bacterial load
in the lung was not investigated. Moreover, long-acting
β2-agonist salmeterol was shown to attenuate Pseudomo-
nas aeruginosa-induced mucosal damage in cultured
human nasal turbinate tissue[36]. Future studies are war-
ranted to: (1) further explore the mechanisms by which
albuterol or formoterol exerts host defense functions.
These include, but are not limited to, studies aimed at
dissecting the involvement of β2-adrenergic receptor vs.
other receptors such as platelet-activating factor (PAF)
receptor and β1-adrenergic receptor[37]; and (2) deter-
mine if β2-agonists are able to reduce lung bacterial load
in COPD patients, especially those with acute exacerba-
tions.
We are aware that our results in human cells do not
support those of a mouse study conducted by Maris and
colleagues[38], who found worsened clearance of non-
typeable Haemophilus influenzae with salmeterol treat-
ment in mice. Several differences exist between the two
studies, including the types of cells cultured in vitro (pri-
mary human bronchial epithelial cells versus mouse alve-
o l a r  m a c r o p h a g e  c e l l  l i n e  M H - S ) ,  t h e  b a c t e r i a  s t u d i e d
(atypical bacteria versus gram negative bacteria), and the
Figure 6 Impact of IL-13 on β2-adrenergic receptor (ADRB2) mRNA expression in bronchial epithelial cells. Compared with non-IL-13 treat-
ment (-), IL-13 significantly lowered ADRB2 mRNA levels in cultured bronchial epithelial cells from asthma (A, n = 8,) and COPD (B, n = 8) patients.
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drugs used. Therefore, a more systematic human study is
needed to further investigate the in vivo effects of β2-ago-
nists on airway mucosal innate immunity. We also realize
that the concentration of albuterol in our study may be
high. Future studies are needed to accurately measure the
concentration of albuterol in airway epithelial lining fluid
of human subjects who receive albuterol, especially the
more active R-isomer.
Host defense function of β2-agonists in the presence of IL-
13
Because a Th2 cytokine milieu exists in both asthma and
COPD, it is important to determine if β2-agonists in the
presence of a Th2 cytokine such as IL-13 function as effi-
ciently as in the absence of a Th2 cytokine. IL-13 was
shown to dampen epithelial cells' host defense response,
as overall Mp levels were higher in the IL-13-treated cells
than those without IL-13. To explore the underlying
mechanisms for the loss of effect of β2-agonists in IL-13-
treated cells, we measured SPLUNC1 levels. We found
that SPLUNC1 levels in the IL-13 treated cells were
markedly lower than those in non-IL-13 treated cells,
suggesting that the presence of IL-13 suppressed cells'
ability to clear bacteria. None of the drugs lowered Mp
levels in this condition. Therefore, IL-13 attenuated the
effects of β2-agonists on lowering Mp levels. To further
investigate the mechanism by which IL-13 inhibited host
defense, we quantified the mRNA levels of ADRB2 from
samples cultured with and without IL-13. Treatment with
IL-13 significantly reduced ADRB2. This may provide an
additional explanation why the IL-13-treated cells did not
show any significant drug effect. Our results, for the first
time, provide evidence that a Th2 cytokine IL-13 can sig-
nificantly decrease ADRB2 expression. This may have
clinical implications to improve the efficacy of β2-agonist
therapy. For example, a therapy such as corticosteroid
treatment, aimed at reducing the Th2 cytokine produc-
tion or activity will be required to improve the antimicro-
bial efficacy of β2-agonists in bot h asthma and COPD
patients.
Conclusions
The goal of current study was to examine if β2-agonists,
the mainstay of therapy in COPD and asthma, exert host
defense functions in airway mucosa. We found that in
normal bronchial epithelial cells without exposure to a
Th2 cytokine IL-13, β2-agonists albuterol and formoterol
decrease Mp load. The antimicrobial effect of albuterol
may be in part through the induction of SPLUNC1 from
airway epithelial cells, but not through its direct bacteri-
cidal activity on Mp. This effect is attenuated in COPD
cells and particularly by IL-13 treatment. Future studies
are needed to determine whether the use of a corticoster-
oid in addition to the β2-agonist can rescue the host
defense functions of airway epithelial cells in COPD cells
and in cells with IL-13 treatment. The combination of a
long-acting β2-agonist with a corticosteroid may be most
beneficial for enhancing endogenous host defense func-
tions of airway epithelial cells in COPD and asthma
patients with a Th2 cytokine background. Additionally, it
may be possible to increase the ADRB2 levels in patients
to enhance the effectiveness of β2-agonists. Long-acting
β2-agonists such as formoterol do not have the same
desensitizing properties as short-acting agonists[13]. This
concept is further supported in our current study in that
ADRB2 expression was significantly decreased by
approximately 2-fold in (R)-albuterol-treated bronchial
epithelial cells compared to negative controls (p = 0.045),
but there was no difference between (R,R)-formoterol-
treated cells and negative controls. Although further
mechanistic studies are needed to reveal the interplay
among short-acting β2-agonists such as (R)-albuterol,
ADRB2, Mp load and SPLUNC1, our current study sug-
gests that the use of a long-acting β2-agonist may not
only induce bronchodilation, but also increase airway
epithelial innate immunity in patients with a lung disease
such as asthma.
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